Boai NKY Medical Holdings Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Junzheng Zhang

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	5yrs
CEO ownership	0.2%
Management average tenure	no data
Board average tenure	5yrs

Recent management updates

Recent updates

Boai NKY Medical Holdings Ltd. (SZSE:300109) Doing What It Can To Lift Shares

Aug 23

Does Boai NKY Medical Holdings (SZSE:300109) Have A Healthy Balance Sheet?

Jul 25

Boai NKY Medical Holdings (SZSE:300109) Is Paying Out A Larger Dividend Than Last Year

Jun 04

We Like These Underlying Return On Capital Trends At Boai NKY Medical Holdings (SZSE:300109)

May 27

Should You Be Adding Boai NKY Medical Holdings (SZSE:300109) To Your Watchlist Today?

Apr 03

Boai NKY Medical Holdings Ltd. (SZSE:300109) Stock Rockets 39% But Many Are Still Ignoring The Company

Mar 04

CEO

Junzheng Zhang (48 yo)

5yrs

Tenure

CN¥312,000

Compensation

Mr. Junzheng Zhang serves as Chairman of the Board and Chief Executive Offier at Boai NKY Medical Holdings Ltd. He served as Secretary of the Board at Boai NKY Medical Holdings Ltd. (formerly known as Boai...

Board Members

Name	Position	Tenure	Compensation	Ownership
Junzheng Zhang	Chairman of the Board & GM	5yrs	CN¥312.00k	0.20% CN¥ 9.8m
Donghu Wang	Director	no data	CN¥336.90k	9.09% CN¥ 454.2m
Hongbo Yang	Vice Chairman of the Board	5yrs	CN¥315.40k	0.22% CN¥ 10.7m
Wei Zhao	Non-Independent Director	5yrs	CN¥120.00k	0.0072% CN¥ 359.1k
Tong Zhou	Independent Director	5yrs	CN¥108.00k	no data
Yunxia Qu	Chairman of the Supervisory Board	5yrs	CN¥173.70k	no data
Chunping Li	Non-Employee Supervisor	5yrs	no data	no data
Dalong Ren	Vice Chairman of the Board	8.8yrs	CN¥259.30k	no data
Haifeng Liu	Supervisor	5yrs	no data	no data
Rui Zhao	Independent Director	2.6yrs	no data	no data
Yongjun Fang	Independent Director	2.6yrs	CN¥90.00k	no data
Tao Chang	Non-Employee Supervisor	1.5yrs	no data	0.0032% CN¥ 161.8k

5.0yrs

Average Tenure

54yo

Average Age

Experienced Board: 300109's board of directors are considered experienced (5 years average tenure).

Boai NKY Medical Holdings Management

Management criteria checks 1/4

Key information

Recent management updates

Boai NKY Medical Holdings Ltd., Annual General Meeting, May 23, 2024

High number of new directors

High number of new and inexperienced directors

Recent updates

Now 26% overvalued

Second quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.29 in 2Q 2023)

Boai NKY Medical Holdings Ltd. (SZSE:300109) Doing What It Can To Lift Shares

Does Boai NKY Medical Holdings (SZSE:300109) Have A Healthy Balance Sheet?

Boai NKY Medical Holdings Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Boai NKY Medical Holdings (SZSE:300109) Is Paying Out A Larger Dividend Than Last Year

Dividend increased to CN¥1.00

Boai NKY Medical Holdings Ltd. Announces Implementation of Final A Share Cash Dividend for 2023, Payable on 07 June 2024

We Like These Underlying Return On Capital Trends At Boai NKY Medical Holdings (SZSE:300109)

Boai NKY Medical Holdings Ltd. Approves Cash Dividend for the Year 2023

Boai NKY Medical Holdings Ltd., Annual General Meeting, May 23, 2024

First quarter 2024 earnings released: EPS: CN¥0.38 (vs CN¥0.39 in 1Q 2023)

Boai NKY Medical Holdings Ltd. Proposes Final Cash Dividend for 2023

Should You Be Adding Boai NKY Medical Holdings (SZSE:300109) To Your Watchlist Today?

Now 23% overvalued after recent price rise

Boai NKY Medical Holdings Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Boai NKY Medical Holdings Ltd. (SZSE:300109) Stock Rockets 39% But Many Are Still Ignoring The Company

Full year 2023 earnings released: EPS: CN¥1.63 (vs CN¥0.88 in FY 2022)

Boai NKY Medical Holdings Ltd. announced that it expects to receive CNY 623 million in funding

Boai NKY Medical Holdings Ltd. announced that it expects to receive CNY 623 million in funding

Investor sentiment deteriorates as stock falls 20%

Boai NKY Medical Holdings Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: EPS: CN¥0.45 (vs CN¥0.42 in 3Q 2022)

Boai NKY Medical Holdings Ltd. to Report Q3, 2023 Results on Oct 25, 2023

Second quarter 2023 earnings released: EPS: CN¥0.44 (vs CN¥0.34 in 2Q 2022)

Boai NKY Medical Holdings Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on May 30, 2023

Boai NKY Medical Holdings Ltd. Approves Cash Dividend for 2022

First quarter 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.10 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.96 (vs CN¥0.91 in FY 2021)

Investor sentiment deteriorated over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.046 in 3Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Gryningskust Holding AB acquired additional 14.0 % minority stake in NeoDynamics AB (publ) (OM:NEOD).

Boai NKY Medical Holdings Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on 30 May 2022

Boai NKY Medical Holdings Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on 30 May 2022

Boai Nky Medical Holdings Ltd. Approves Cash Dividend

Boai NKY Medical Holdings Ltd. Proposes Final Cash Dividend for the Year 2021

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Boai NKY Medical Holdings Ltd. (SZSE:300109) commences a Equity Buyback Plan under the authorization approved on December 21, 2021.

Third quarter 2021 earnings released: EPS CN¥0.046 (vs CN¥0.08 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.067 (vs CN¥0.12 in 2Q 2020)

Abcam plc (AIM:ABC) entered into a definitive agreement to acquire BioVision, Inc. from Boai NKY Medical Holdings Ltd. (SZSE:300109) for approximately $340 million.

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Shanghai Haitong Securities Assets Management Co.,Ltd. completed the acquisition of 3% stake in Boai NKY Medical Holdings Ltd. (SZSE:300109) from Wang Donghu.

Boai Nky Medical Holdings Ltd. Approves Final Cash Dividend for 2020

Boai NKY Medical Holdings Ltd. Proposes Final Cash Dividend for 2020

First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.04 in 1Q 2020)

Investor sentiment deteriorated over the past week

New 90-day low: CN¥11.20

New 90-day low: CN¥11.89

Ningbo Tianlong Electronics Co., Ltd. (SHSE:603266) entered into a equity transfer agreement to acquire 4.1818% stake in Wuhan First Bioscience Inc. from Boai NKY Medical Holdings Ltd. (SZSE:300109) for CNY 14 million.

New 90-day low: CN¥13.80

New 90-day low: CN¥15.06

New 90-day low: CN¥16.55

Third quarter earnings released

Market bids up stock over the past week

New 90-day high: CN¥19.40

New 90-day high: CN¥19.24

Fang Huasheng and Ren Dalong acquired 18.99% stake in Boai NKY Pharmaceuticals Ltd. (SZSE:300109).

New 90-day high - CN¥18.63

Earnings released

Boai NKY Medical Holdings Ltd. to Report First Half, 2020 Results on Aug 27, 2020

New 90-day high - CN¥18.55

CEO

Tenure

Compensation